Endocrine Pharmacology Practice Questions

Q: Which drug is used in the management of renal osteodystrophy?

All of the above. **Explanation:** Renal osteodystrophy is a complex bone disorder occurring in chronic kidney disease (CKD) due to the kidney's inability to activate Vitamin D and excrete phosphate. The core pathophysiology involves a deficiency of **1-alpha-hydroxylase**, the enzyme responsible for converting Calcifediol into the active form, Calcitriol. **Why "All of the above" is correct:** Management aims to maintain calcium levels and suppress secondary hyperparathyroidism. * **Calcitriol (1,25-dihydroxyvitamin D3):** This is the active form of Vitamin D. Since the failing kidney cannot perform 1-alpha-hydroxylation, providing the active form directly is the most physiological approach to bypass the renal defect. * **Calcifediol (25-hydroxyvitamin D3):** While it requires renal activation, high doses of Calcifediol can still be used in early stages of CKD or to correct underlying nutritional deficiency. * **Vitamin D (Ergocalciferol/Cholecalciferol):** Native Vitamin D is often supplemented to ensure the liver has enough substrate to produce Calcifediol, maintaining overall Vitamin D stores. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Calcitriol is generally preferred in advanced CKD because it does not require renal activation. * **Alfacalcidol:** Another frequently asked prodrug; it is 1-alpha-hydroxyvitamin D3. It requires **hepatic** activation but bypasses the **renal** step, making it highly effective in renal failure. * **Cinacalcet:** A calcimimetic often used alongside Vitamin D analogs to further suppress Parathyroid Hormone (PTH) by increasing the sensitivity of calcium-sensing receptors. * **Phosphate Binders:** (e.g., Sevelamer, Calcium Acetate) are essential adjuncts to prevent hyperphosphatemia, which worsens bone loss.

Q: A 48-year-old woman presents with vulval pruritus. On examination, there is erythema of the external genitalia. She is a known diabetic for 10 years. Her HbA1c level reduced to 6.6% from a previous value of 7.8% four months ago. What medication is most probably responsible for her symptoms?

Canagliflozin. ### Explanation **Correct Answer: B. Canagliflozin** **Mechanism and Clinical Correlation:** The patient is presenting with symptoms of **Vulvovaginal Candidiasis** (vulval pruritus and erythema), a classic side effect of **SGLT-2 inhibitors** like Canagliflozin. SGLT-2 inhibitors work by inhibiting glucose reabsorption in the proximal convoluted tubule of the kidney, leading to **therapeutic glucosuria**. While this effectively lowers HbA1c (as seen in this patient), the increased concentration of glucose in the urinary tract provides a rich medium for the growth of fungi and bacteria. This significantly increases the risk of genital mycotic infections (candidiasis) and urinary tract infections (UTIs). **Analysis of Incorrect Options:** * **A. Sitagliptin (DPP-4 Inhibitor):** These drugs are weight-neutral and generally well-tolerated. Their most characteristic side effects include nasopharyngitis and a rare risk of pancreatitis, but they do not cause glucosuria or genital infections. * **C. Acarbose (Alpha-glucosidase Inhibitor):** This drug acts locally in the GI tract to delay carbohydrate absorption. Its primary side effects are gastrointestinal (flatulence, diarrhea, abdominal bloating), not genitourinary. * **D. Exenatide (GLP-1 Agonist):** These injectable drugs cause delayed gastric emptying and weight loss. Common side effects include nausea, vomiting, and a risk of pancreatitis, but not mycotic infections. **High-Yield Clinical Pearls for NEET-PG:** * **SGLT-2 Inhibitors ("-gliflozins"):** Associated with weight loss, blood pressure reduction, and cardio-renal protection. * **Key Side Effects:** Genital mycotic infections (most common), UTIs, osmotic diuresis (hypotension/dehydration), and a rare but serious risk of **Euglycemic Diabetic Ketoacidosis (eDKA)**. * **Fournier’s Gangrene:** A rare, life-threatening necrotizing fasciitis of the perineum associated with SGLT-2 inhibitor use.

Q: Which steroid has the least mineralocorticoid activity?

Methylprednisolone. **Explanation:** The correct answer is **Methylprednisolone**. The classification of corticosteroids is based on their relative **glucocorticoid** (anti-inflammatory) and **mineralocorticoid** (salt-retaining) potencies. Glucocorticoids exert their mineralocorticoid effects by binding to aldosterone receptors in the renal distal tubules, leading to sodium retention and potassium excretion. * **Methylprednisolone:** This is a synthetic intermediate-acting glucocorticoid. It has been chemically modified to enhance anti-inflammatory potency while significantly reducing mineralocorticoid activity. Its salt-retaining potency is near zero (0.5 compared to Hydrocortisone's 1), making it the correct choice among the options. **Analysis of Incorrect Options:** * **Aldosterone:** The primary endogenous mineralocorticoid. It has maximal salt-retaining activity and negligible anti-inflammatory effects. * **Deoxycorticosterone acetate (DOCA):** A precursor of aldosterone. It is a pure mineralocorticoid used experimentally to induce hypertension; it lacks glucocorticoid activity. * **Hydrocortisone (Cortisol):** The main endogenous glucocorticoid. It possesses significant mineralocorticoid activity (ratio of 1:1). It is often avoided in patients where fluid retention is a concern (e.g., heart failure or hypertension). **NEET-PG High-Yield Pearls:** * **Dexamethasone & Betamethasone:** These are long-acting steroids with **zero** mineralocorticoid activity. If they were an option, they would be "less" than methylprednisolone. * **Fludrocortisone:** A synthetic steroid with the highest mineralocorticoid-to-glucocorticoid ratio used clinically (primarily for Addison’s disease). * **Mnemonic for Potency (Least to Most):** **C**ortisol < **P**rednisolone < **M**ethylprednisolone < **D**examethasone (**C**an **P**eter **M**ake **D**inner).

Q: Which of the following are uses of danazol?

All of the above. **Explanation:** **Danazol** is a synthetic ethisterone derivative with a complex pharmacological profile. It acts as a **weak androgen** and a **gonadotropin inhibitor**, creating a "pseudo-menopausal" state by suppressing the pituitary-ovarian axis (inhibiting LH and FSH surges). **Why "All of the Above" is Correct:** 1. **Endometriosis (Option A):** This is the primary clinical use. Danazol causes atrophy of ectopic endometrial tissue by inhibiting steroidogenesis and creating a hypoestrogenic, hyperandrogenic environment. 2. **Menorrhagia (Option B):** By suppressing the endometrial lining and inducing amenorrhea, it is effective in reducing heavy menstrual bleeding, particularly when associated with fibroids or dysfunctional uterine bleeding. 3. **Hereditary Angioneurotic Edema (HANE) (Option C):** This is a high-yield indication. Danazol increases the hepatic synthesis of the **C1 esterase inhibitor** protein, which is deficient in patients with HANE, thereby preventing attacks. **Clinical Pearls for NEET-PG:** * **Mechanism:** It is a "selective pituitary gonadotropin inhibitor" and also directly inhibits several enzymes involved in adrenal and gonadal steroidogenesis. * **Side Effects:** Due to its androgenic nature, it commonly causes **weight gain, acne, hirsutism, deepening of the voice, and decreased breast size.** * **Contraindications:** It should be avoided in pregnancy (teratogenic—causes virilization of female fetuses) and in patients with significant hepatic dysfunction. * **Other Uses:** It is occasionally used in **Fibrocystic Breast Disease** and **Immune Thrombocytopenic Purpura (ITP)**.

Q: Which of the following is not a starting criterion for sulfonylurea therapy?

Total pancreatectomy. ### Explanation **1. Why "Total Pancreatectomy" is the Correct Answer:** Sulfonylureas (e.g., Glibenclamide, Glimepiride) are **insulin secretagogues** [1], [3]. Their primary mechanism of action involves binding to the SUR1 subunit of ATP-sensitive potassium channels on the **pancreatic beta cells** [1], [3]. This leads to cell depolarization, calcium influx, and the subsequent release of pre-formed insulin [3]. In a patient who has undergone a **total pancreatectomy**, there are no functional beta cells remaining. Since sulfonylureas require endogenous insulin stores to function, they are absolutely ineffective and contraindicated in this scenario. These patients have "surgical diabetes" and require lifelong exogenous insulin therapy. **2. Analysis of Incorrect Options:** * **B. Non-insulin-dependent diabetes mellitus (NIDDM):** This is the primary indication for sulfonylureas [1]. In Type 2 DM, beta cells are still functional but often sluggish; sulfonylureas help "kickstart" insulin secretion. * **C. Diabetes diagnosed after 40-60 years of age:** Sulfonylureas are most effective in patients who develop diabetes later in life (maturity-onset). A diagnosis after age 40, a duration of disease less than 5 years, and a daily insulin requirement of less than 40 units are traditional predictors of a good response to sulfonylureas. **3. NEET-PG High-Yield Pearls:** * **Mechanism:** Blocks $K_{ATP}$ channels $\rightarrow$ Depolarization $\rightarrow$ $Ca^{2+}$ influx $\rightarrow$ Insulin release [3]. * **Primary Side Effect:** Hypoglycemia (most common with Glyburide/Glibenclamide due to long half-life) and weight gain [2]. * **Disulfiram-like reaction:** Classically associated with first-generation sulfonylureas like **Chlorpropamide**. * **Failure Criteria:** "Primary failure" occurs if the drug never works; "Secondary failure" occurs when beta-cell function declines over years of treatment, eventually requiring insulin [1].

Q: Cabergoline is the drug of choice for which condition?

Prolactinoma. **Explanation:** **Correct Answer: C. Prolactinoma** **Mechanism and Rationale:** Cabergoline is a potent, long-acting **ergot-derived Dopamine (D2) receptor agonist** [1]. In the anterior pituitary, dopamine acts as the primary inhibitory factor for prolactin secretion. By stimulating D2 receptors on lactotrophs, Cabergoline effectively suppresses prolactin synthesis and release. It is considered the **Drug of Choice (DOC)** for prolactinomas because it is more effective at shrinking tumor size and normalizing prolactin levels compared to Bromocriptine, with the added benefit of a better side-effect profile and a longer half-life (allowing for once or twice weekly dosing) [1], [2]. **Analysis of Incorrect Options:** * **A. Parkinsonism:** While dopamine agonists (like Bromocriptine, Pramipexole, or Ropinirole) are used in Parkinson’s, Cabergoline is rarely used today for this indication due to the risk of **cardiac valvular fibrosis** at the high doses required for motor symptoms. * **B. Alzheimer’s Disease:** This condition is characterized by a cholinergic deficit. Treatment involves cholinesterase inhibitors (Donepezil) or NMDA antagonists (Memantine), not dopamine agonists. * **D. Galactorrhea:** While Cabergoline treats galactorrhea, the question asks for the specific clinical *condition*. Galactorrhea is a *symptom* often caused by a prolactinoma. In the context of NEET-PG, always prioritize the definitive pathological diagnosis (Prolactinoma) over the clinical sign. **High-Yield Clinical Pearls for NEET-PG:** * **Half-life:** Cabergoline has a very long half-life (~65 hours), enabling weekly dosing [1]. * **Side Effects:** Nausea and orthostatic hypotension are common. Long-term high-dose use requires monitoring for cardiac valvulopathy via echocardiography [3]. * **Pregnancy:** Bromocriptine is generally preferred if pregnancy is desired due to a longer track record of safety data, though Cabergoline is increasingly used.

Q: All of the following statements about nateglinide are true except?

It decreases insulin resistance. **Explanation:** **Nateglinide** belongs to the **Meglitinide (Glinide)** class of oral hypoglycemic agents. The core mechanism of this class is the stimulation of insulin secretion from the pancreas, making them **insulin secretagogues**, not insulin sensitizers. 1. **Why Option C is the correct answer (False statement):** Nateglinide does **not** decrease insulin resistance. Drugs that decrease insulin resistance (insulin sensitizers) include Biguanides (Metformin) and Thiazolidinediones (Pioglitazone). Nateglinide works solely by increasing the output of insulin from functional pancreatic beta cells. 2. **Analysis of other options:** * **Option A (True):** Nateglinide has a very rapid onset and short duration of action. It is specifically taken just before meals to mimic the first-phase insulin response, effectively controlling **post-prandial hyperglycemia**. * **Option B (True):** Because of its short half-life and "quick-on, quick-off" action, the risk of delayed or prolonged **hypoglycemia is significantly lower** compared to long-acting sulfonylureas (like Glibenclamide). * **Option D (True):** Like sulfonylureas, nateglinide binds to the **SUR1 receptor** on the ATP-sensitive $K^+$ channels of pancreatic $\beta$-cells, causing channel closure, depolarization, $Ca^{2+}$ influx, and subsequent **insulin release**. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Closes ATP-sensitive $K^+$ channels (distinct binding site from sulfonylureas). * **Metabolism:** Primarily metabolized by the liver; it is safer than sulfonylureas in patients with mild-to-moderate renal impairment. * **Dosing:** Known as "post-prandial glucose regulators"; if a meal is skipped, the dose must be skipped to avoid hypoglycemia. * **Weight Gain:** Like all secretagogues, nateglinide can cause modest weight gain.

Q: What is the drug of choice for managing hyperglycemia in diabetic ketoacidosis?

Regular insulin. **Explanation:** **1. Why Regular Insulin is the Correct Answer:** Regular insulin (Short-acting) is the drug of choice for Diabetic Ketoacidosis (DKA) because it is the **only** insulin formulation that can be administered **intravenously (IV)**. In DKA, there is severe dehydration and poor peripheral perfusion, making subcutaneous absorption unpredictable. IV administration ensures 100% bioavailability and a rapid onset of action. Its short half-life (approx. 5–10 minutes when given IV) allows for precise titration based on hourly blood glucose monitoring, minimizing the risk of sudden hypoglycemia or cerebral edema. **2. Why Other Options are Incorrect:** * **Lente insulin:** This is an intermediate-acting insulin. It has a slow onset and prolonged duration, making it unsuitable for the acute, minute-to-minute management required in DKA. * **Glyburide:** This is a second-generation Sulfonylurea (oral hypoglycemic). It works by stimulating pancreatic beta cells to release insulin. In DKA, there is an absolute or relative insulin deficiency and severe metabolic derangement that oral agents cannot correct. * **70/30 insulin:** This is a premixed combination (70% NPH, 30% Regular). Because it contains NPH (intermediate-acting), it cannot be given intravenously and is used for chronic maintenance, not emergencies. **3. High-Yield Clinical Pearls for NEET-PG:** * **Route:** In DKA, Regular insulin is given as a continuous low-dose IV infusion (0.1 units/kg/hour). * **Potassium Warning:** Always check potassium levels before starting insulin. Insulin shifts $K^+$ into cells; if the patient is hypokalemic ($<3.3$ mEq/L), starting insulin can cause fatal arrhythmias. * **The Goal:** The primary goal of insulin in DKA is not just to lower glucose, but to **stop ketogenesis** by inhibiting hormone-sensitive lipase. * **Switching:** Transition to subcutaneous insulin only when the anion gap has closed and the patient is able to eat.

Question 1

Which drug is used in the management of renal osteodystrophy?

Accepted Answer

All of the above

Answer

Vitamin D

Answer

Calcitriol

Answer

Calcifediol

Question 2

A 48-year-old woman presents with vulval pruritus. On examination, there is erythema of the external genitalia. She is a known diabetic for 10 years. Her HbA1c level reduced to 6.6% from a previous value of 7.8% four months ago. What medication is most probably responsible for her symptoms?

Accepted Answer

Canagliflozin

Answer

Sitagliptin

Answer

Acarbose

Answer

Exenatide

Question 3

Which steroid has the least mineralocorticoid activity?

Accepted Answer

Methylprednisolone

Answer

Aldosterone

Answer

Deoxycorticosterone acetate (DOCA)

Answer

Hydrocortisone

Question 4

Which of the following are uses of danazol?

Accepted Answer

All of the above

Answer

Endometriosis

Answer

Menorrhagia

Answer

Hereditary angioneurotic edema

Question 5

Paricalcitol is FDA-approved for which of the following conditions?

Accepted Answer

Secondary hyperparathyroidism

Answer

Rickets

Answer

Osteomalacia

Answer

Primary hyperparathyroidism

Question 6

Which of the following is not a starting criterion for sulfonylurea therapy?

Accepted Answer

Total pancreatectomy

Answer

Non-insulin-dependent diabetes mellitus (NIDDM)

Answer

Diabetes diagnosed after 60 years of age

Answer

None of the above

Question 7

Cabergoline is the drug of choice for which condition?

Accepted Answer

Prolactinoma

Answer

Parkinsonism

Answer

Alzheimer's disease

Answer

Galactorrhea

Question 8

A 30-year-old female with a 15-year history of asthma presents to the emergency room with left elbow pain. Physical examination reveals tenderness and swelling over the olecranon process. An X-ray of the left arm reveals a fracture. Her medications include oral prednisone and albuterol aerosol. By which of the following mechanisms might corticosteroids have contributed to her fracture?

Accepted Answer

Increased osteoclastic bone resorption and decreased osteoblastic bone formation

Answer

Decreased osteoblastic bone formation only

Answer

Decreased osteoblastic bone formation and osteoclastic bone resorption

Answer

Increased osteoclastic bone resorption only

Question 9

All of the following statements about nateglinide are true except?

Accepted Answer

It decreases insulin resistance

Answer

Decreases post-prandial hyperglycemia

Answer

Hypoglycemia is less common than with sulfonylureas

Answer

It acts by releasing insulin

Question 10

What is the drug of choice for managing hyperglycemia in diabetic ketoacidosis?

Accepted Answer

Regular insulin

Answer

Lente insulin

Answer

Glyburide

Answer

70/30 insulin

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?